Form 4: Neurocrine Biosciences Director Stephen Sherwin Exercises Options and Sells Shares

Director Stephen Sherwin exercised stock options and sold Neurocrine Biosciences (NBIX) shares on May 29, 2024, according to a Form 4 filing with the SEC.

Summary

• On May 29, 2024, Stephen Sherwin, a director of Neurocrine Biosciences, exercised non-qualified stock options to acquire 25,000 shares at $42.76 and 15,000 shares at $47.89.
• Simultaneously, Sherwin sold 25,000 shares and 15,000 shares of common stock at a weighted average price of $133.4622 and $133.4673 respectively.
• Following these transactions, Sherwin directly owns 26,504 shares of Neurocrine Biosciences common stock.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 28, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reflects routine transactions by a company director. The use of a 10b5-1 plan suggests pre-planned sales, not necessarily a reflection of current sentiment.

Industry Context

This filing is a routine disclosure of insider transactions. Monitoring such filings can provide insights into management's perspective on the company's valuation and future prospects, although individual transactions may not always be indicative of broader trends.

Comparison to Industry Standards

• Insider trading activity is common across publicly listed companies, and is regulated by the SEC.
• Rule 10b5-1 trading plans are a standard mechanism used by insiders to sell shares while avoiding accusations of trading on non-public information.
• Comparable companies such as Biogen, Vertex Pharmaceuticals, and Amgen also have regular Form 4 filings related to insider transactions.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
• The impact on employees, customers, suppliers, and creditors is likely to be negligible.

Key Dates